Anthracycline-related cardiotoxicity in childhood cancer survivors
Lipshultz SE, Karnik R, Sambatakos P, Franco VI, Ross SW, Miller TL. Anthracycline-related cardiotoxicity in childhood cancer survivors. Current Opinion In Cardiology 2014, 29: 103-112. PMID: 24284979, DOI: 10.1097/hco.0000000000000034.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAnthracyclinesAntineoplastic AgentsCardiotonic AgentsChildDisease ProgressionHeart FailureHeart TransplantationHuman Growth HormoneHumansNeoplasmsVentricular Dysfunction, LeftConceptsAnthracycline-related cardiotoxicityCardiovascular complicationsAnthracycline treatmentRisk factorsCardioprotective agentGrowth hormone replacement therapyPrevention of cardiotoxicityHormone replacement therapySerious cardiovascular complicationsChildhood cancer survivorsLong-term outcomesUse of biomarkersDosage of anthracyclinesCardiac transplantationCardiac dysfunctionCancer survivorsCardiac injuryClinical manifestationsReplacement therapyEarly recognitionChildhood cancerCardiotoxic effectsΒ-blockersEnzyme inhibitorsCardiotoxicity